cdmo cell and gene therapy selection: why a cell and gene therapy cdmo is chosen on capacity, containment and demonstrated experience rather than on price, what cell and gene therapy manufacturing commits a programme to in suite time and analytics, how cgt manufacturing partners and a cgt cdmo differ from a conventional biologics site, and what has to be settled before a slot is booked
Cell and gene therapy manufacture differs from conventional biologics in ways that change how a provider is chosen: batches are small and often patient-specific, the starting material may be a person's cells with a fixed schedule, and analytical methods are less standardised. Capacity and experience in your exact modality matter more than price. This page covers the questions that separate providers.
- the FDA cGMP rule that applies once material is destined for a drug product
- Part 211
- the ICH guideline on deriving and characterising cell substrates
- Q5D
- good laboratory practice for nonclinical studies, 21 CFR
- Part 58
Figures in this panel are the rules a contract biologics service is bought and audited against, named from the regulations and guidelines themselves and linked in the sources below. They are identifiers, not prices: BioBricks publishes verified prices for synthesis services only, and does not imply a services index it has not measured.
- 4 vendor service pages verifiedevery figure matched verbatim to the vendor's page
- Quoted and dated, never estimatedlast verification pass 2026-08-24
- 1 service classes coveredeach with measured search demand behind it
The questions that separate providers
- Experience in your modality specifically. Viral vector production, autologous cell processing, allogeneic manufacture and gene-edited products are different operations with different equipment and different problems. Ask how many programmes in your exact modality the site has run, and ask to speak to one of those sponsors.
- Suite capacity and what a slot means. Capacity is measured in suites and in the changeover between campaigns, and for autologous products in slots per period. Establish what is contractually reserved, what happens if your timeline slips, and what happens if theirs does.
- Starting material logistics. Where the starting material is a patient's cells, the chain of identity and the chain of custody from collection to manufacture and back are part of the service. Ask how these are managed, what the systems are, and what happens when a shipment is delayed.
- Analytics and potency. Potency assays for these products are frequently the hardest part of the programme and are less standardised than for conventional biologics. Establish who develops them, who owns them, and how they transfer, because this is where timelines slip most often.
- Regulatory experience and inspection history. Ask which authorities have inspected the site, when, for which modality, and how the site supported previous sponsors' filings. Experience of the regulatory path in your modality is worth more than nominal capacity.
Technology transfer is the highest risk stage
Processes in this field are frequently less defined than in conventional biologics, and more of the knowledge sits in people rather than in documents. Ask how transfer is run, who leads it, how long it takes and how comparability is demonstrated at the receiving site.
Budget for the transfer to reveal process gaps. Where it does, finding them at the receiving site is the expected outcome rather than a failure, and a provider that plans for it is a better partner than one that does not.
What to settle in the contract
Ownership of the process, the analytical methods and any improvement; what happens when a batch fails and who pays; the consequences of slot slippage on both sides; and the position on materials and licences embedded in the process.
For autologous products, also settle the failure case for an individual patient batch, because the consequences there are not only commercial.
Common questions
- How do I choose a cell and gene therapy CDMO?
- On experience in your exact modality, on real suite capacity and what a reserved slot contractually means, on starting material logistics, and on analytical capability. Price is rarely the deciding factor in this field.
- Why are analytics such a problem here?
- Potency assays for cell and gene therapy products are less standardised than for conventional biologics and are frequently the hardest part of a programme. Establish who develops them, who owns them and how they transfer.
- What makes technology transfer risky in this field?
- Processes are often less defined and more of the knowledge sits with people rather than in documents, so transfer commonly reveals gaps. A provider that plans for that is a better partner than one that assumes a clean handover.
- What does a manufacturing slot actually guarantee?
- Only what the contract says. Establish what is reserved, what happens if your timeline slips and what happens if the provider's does, because capacity in this field is genuinely constrained.
Get a shortlist for your project
Browse by service class
Sources
Cite or embed this figure
The median advertised gene synthesis price per base pair in the US research synthesis services market was $0.11 in August 2026, across 4 verified vendor service pages recorded in BioBricks Synthesis Price Index.
Cite as: "BioBricks Synthesis Price Index", updated 2026-08-24, https://biobricks.org/cdmo-cell-and-gene-therapy/.